Trials / Conditions / Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum Disorder (NMOSD)
6 registered clinical trials studyying Neuromyelitis Optica Spectrum Disorder (NMOSD) — 4 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Anti NCT07526493 | Tongji Hospital | Phase 1 |
| Suspended | Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia NCT07247292 | AstraZeneca | — |
| Recruiting | Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD NCT06780709 | Icahn School of Medicine at Mount Sinai | N/A |
| Recruiting | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy NCT06312644 | Alexion Pharmaceuticals, Inc. | — |
| Not Yet Recruiting | A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients NCT06557174 | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica NCT07032337 | Samsung Medical Center | — |